{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:52:57Z","timestamp":1791568377167,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00292-021-00934-9","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T12:02:26Z","timestamp":1617710546000},"page":"270-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Aktualisierte WHO-Klassifikation der Tumoren der Mamma: Die wichtigsten \u00c4nderungen","Updated WHO classification of tumors of the breast: the most important changes"],"prefix":"10.1007","volume":"42","author":[{"given":"Annette","family":"Lebeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison\u00a0KH, Hammond\u00a0MEH, Dowsett\u00a0M et\u00a0al (2020) Estrogen and Progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J\u00a0Clin Oncol 38:1346\u20131366","journal-title":"J Clin Oncol"},{"key":"934_CR2","unstructured":"Deutsche Krebsgesellschaft, Deutsche Gesellschaft F\u00fcr Gyn\u00e4kologie Und Geburtshilfe (2020) S3-Leitlinie \u201eFr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms\u201c. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Mammakarzinom_4_0\/Version_4.3\/LL_Mammakarzinom_Langversion_4.3.pdf. Zugegriffen: 31. Jan. 2021"},{"key":"934_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston\u00a0CW, Ellis\u00a0IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a\u00a0large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","volume":"24","author":"N Bijker","year":"2006","unstructured":"EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker\u00a0N, Meijnen\u00a0P, Peterse\u00a0JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853\u2014A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J\u00a0Clin Oncol 24:3381\u20133387","journal-title":"J Clin Oncol"},{"key":"934_CR5","unstructured":"https:\/\/www.tilsinbreastcancer.org\/. Zugegriffen: 31. Jan. 2021"},{"key":"934_CR6","unstructured":"https:\/\/www.ki67inbreastcancerwg.org\/. Zugegriffen: 31. Jan. 2021"},{"key":"934_CR7","volume-title":"WHO classification of tumours of the breast","author":"SR Lakhani","year":"2012","unstructured":"Lakhani\u00a0SR, Ellis\u00a0I, Schnitt\u00a0S et\u00a0al (2012) WHO classification of tumours of the breast. IARC Press, Lyon"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00292-019-0578-3","volume":"40","author":"A Lebeau","year":"2019","unstructured":"Lebeau\u00a0A, Denkert\u00a0C, Sinn\u00a0P et\u00a0al (2019) Update of the German S3 breast cancer guideline: what is new for pathologists? Pathologe 40:185\u2013198","journal-title":"Pathologe"},{"key":"934_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201","author":"TO Nielsen","year":"2020","unstructured":"Nielsen\u00a0TO, Leung\u00a0SCY, Rimm\u00a0DL et\u00a0al (2020) Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J\u00a0Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djaa201","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi\u00a0G, Klimstra\u00a0DS, Abedi-Ardekani\u00a0B et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770\u20131786","journal-title":"Mod Pathol"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado\u00a0R, Denkert\u00a0C, Demaria\u00a0S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259\u2013271","journal-title":"Ann Oncol"},{"key":"934_CR12","volume-title":"International histological classification of tumours No. 2\u2014Histological typing of breast tumours","year":"1968","unstructured":"Scarff\u00a0RW, Torloni\u00a0H (Hrsg) (1968) International histological classification of tumours No. 2\u2014Histological typing of breast tumours. World Health Organization, Geneva"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"151481","DOI":"10.1016\/j.anndiagpath.2020.151481","volume":"45","author":"SJ Schnitt","year":"2020","unstructured":"Schnitt\u00a0SJ, Brogi\u00a0E, Chen\u00a0YY et\u00a0al (2020) American registry of pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications. Ann Diagn Pathol 45:151481","journal-title":"Ann Diagn Pathol"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan\u00a0PH, Ellis\u00a0I, Allison\u00a0K et\u00a0al (2020) The 2019 World Health Organization classification of tumours of the breast. Histopathology 77:181\u2013185","journal-title":"Histopathology"},{"key":"934_CR15","volume-title":"World Health Organisation classification of tumours. Pathology and genetics of tumours of the breast and female genital organs","year":"2003","unstructured":"Tavassoli\u00a0FA, Devilee\u00a0P (Hrsg) (2003) World Health Organisation classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jclinpath-2012-200733","volume":"65","author":"RA Walker","year":"2012","unstructured":"Walker\u00a0RA, Hanby\u00a0A, Pinder\u00a0SE et\u00a0al (2012) Current issues in diagnostic breast pathology. J\u00a0Clin Pathol 65:771\u2013785","journal-title":"J Clin Pathol"},{"key":"934_CR17","volume-title":"WHO classification of tumours\u2014Breast tumours","author":"WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"WHO Classification of Tumours Editorial Board (2019) WHO classification of tumours\u2014Breast tumours. International Agency for Research on Cancer, Lyon"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2014.59.7559","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff\u00a0AC, Hammond\u00a0ME, Hicks\u00a0DG et\u00a0al (2015) Reply to E.A. Rakha et\u00a0al. J\u00a0Clin Oncol 33:1302\u20131304","journal-title":"J Clin Oncol"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff\u00a0AC, Hammond\u00a0ME, Hicks\u00a0DG et\u00a0al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J\u00a0Clin Oncol 31:3997\u20134013","journal-title":"J Clin Oncol"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff\u00a0AC, Hammond\u00a0MEH, Allison\u00a0KH et\u00a0al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J\u00a0Clin Oncol 36:2105\u20132122","journal-title":"J Clin Oncol"},{"key":"934_CR21","volume-title":"International histological classification of tumours No. 2\u2014Histological typing of breast tumours","author":"World Health Organization","year":"1981","unstructured":"World Health Organization (1981) International histological classification of tumours No. 2\u2014Histological typing of breast tumours. World Health Organization, Geneva"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-00934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-021-00934-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-00934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:04:39Z","timestamp":1619690679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-021-00934-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s00292-021-00934-9","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"17 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Lebeau \u00fcbte f\u00fcr die Firmen Roche Pharma, AstraZeneca, Novartis und MSD eine Vortragst\u00e4tigkeit sowie f\u00fcr die Firmen Roche Pharma, Novartis, MSD und Daiichi Sankyo eine Beratert\u00e4tigkeit aus. Sie erhielt von der Firma Roche Pharma AG Studienunterst\u00fctzung. C.\u00a0Denkert war Mitgr\u00fcnder der Firma Sividon Diagnostics (jetzt Myriad) und ist in Kooperation mit der Firma vmScope an der Entwicklung von standardisierten Bildanalysesystemen, u.\u202fa. f\u00fcr Ki-67 und TILs beteiligt. Er \u00fcbte f\u00fcr die Firmen Roche, AstraZeneca, Novartis, Daiichi, Myriad, Merck und MSD eine Beratert\u00e4tigkeit aus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegeben ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}